Edison Investment Research - Pharmaceuticals & healthcare - Australis Capital: Australis Capital announced on 18 February 2020 that the proposed merger with Folium Biosciences would be called off following the discovery of ‘new relevant information with regard to Folium.’ Further details have not been disclosed. Australis previously planned on divesting its THC associated assets, which we now assume will not proceed following the termination of the merger agreement.
ISIN: CA05259R1073
Original Article: Australis Capital (AUSA) - Folium merger cancelled